Lifeward wins CE mark for ReWalk 7 personal endoskeleton
September 8, 2025
Lifeward (Nasdaq:LFWD) announced today that it received CE mark approval for its ReWalk 7 personal exoskeleton.
Lifeward (Nasdaq:LFWD) announced today that it received CE mark approval for its ReWalk 7 personal exoskeleton.
The company raised $250 million in July to expand its manufacturing capabilities and establish multiple teams to support the launch.
DENVER, Sept. 4, 2025 /PRNewswire/ — Ultrasound AI™, Inc., a pioneer in artificial intelligence for medical imaging, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,369,883, “Artificial Intelligence System for Determining Clinical Values through Medical Imaging.” The patent protects the company’s proprietary system for determining current or future clinical or laboratory values directly from non-invasive medical images such as ultrasound.
Ypsomed announced that the FDA granted 510(k) clearance for SmartPilot, a digital connectivity add-on for its Ypsomate autoinjectors.
Roche announced today that it received CE mark approval for its port delivery platform containing its Susvimo therapeutic.
Medtronic (NYSE: MDT)+
announced that it received regulatory approval in Japan for its Symplicity Spyral renal denervation (RDN) system.
GE HealthCare (Nasdaq: GEHC)+
announced that it received FDA 510(k) clearance for its Revolution Vibe CT imaging system.
Surgerii Robotics announced on LinkedIn today that its Shurui single-port surgical robot garnered CE mark approval in Europe.
The submission for CT:VQ was supported by a clinical validation package that spanned a variety of lung conditions.
Imperative Care announced today that the FDA granted 510(k) clearance for its Symphony thrombectomy system to treat pulmonary embolism (PE).